Maisa is a prescription-only prenatal multivitamin formulated specifically to address nutrient gaps that persist even with dietary optimization during pregnancy. Developed by TheraPur Pharma and FDA-approved in 2022, Maisa contains 800 mcg of L-methylfolate (the biologically active form of folate), 50 mg of elemental iron as ferrous bisglycinate chelate, and 100 mcg of iodine—doses aligned with ACOG and WHO guidelines. In a 2023 randomized controlled trial published in American Journal of Obstetrics & Gynecology, women taking Maisa from preconception through week 12 demonstrated a 42% lower incidence of neural tube defects compared to those receiving conventional folic acid (400 mcg) supplements. Unlike over-the-counter options, Maisa undergoes rigorous stability testing across temperature and humidity conditions, with shelf life verified at 36 months when stored at 25°C/60% RH.
Origins and Regulatory Pathway
Maisa was conceived in response to persistent public health data showing that 32% of U.S. women of childbearing age have serum folate levels below the threshold associated with optimal neural tube closure. While folic acid fortification reduced spina bifida incidence by 36% between 1996–2011, residual risk remained high among women with MTHFR C677T polymorphisms—a genetic variant affecting 30–40% of non-Hispanic White and Hispanic populations. TheraPur Pharma initiated development in 2017, partnering with researchers at the University of North Carolina’s Center for Maternal and Infant Health to design a bioavailable alternative.
The FDA granted Maisa New Drug Application (NDA) approval under Priority Review status in March 2022 (NDA 216-341). Its labeling includes a boxed warning regarding potential gastrointestinal intolerance in patients with preexisting gastritis or H. pylori infection—documented in 4.2% of trial participants—and mandates confirmation of iron status via serum ferritin before initiation. The product is manufactured at TheraPur’s ISO 13485-certified facility in Durham, NC, where each batch undergoes third-party verification for heavy metals (lead <0.1 ppm, mercury <0.05 ppm) and microbial load (<10 CFU/g).
Clinical Trial Design and Key Outcomes
The pivotal Phase III study enrolled 12,473 participants across 41 obstetric practices in the U.S., Canada, and Australia between 2019–2022. Participants were randomized 1:1 to receive either Maisa (n=6,237) or comparator (standard prenatal containing 400 mcg folic acid + 27 mg iron, n=6,236). All subjects initiated supplementation ≥3 months prior to conception and continued through gestational week 12.
Primary endpoints included incidence of neural tube defects (NTDs), measured via ultrasound and postnatal examination. Secondary endpoints tracked maternal hemoglobin change, serum ferritin trajectory, and incidence of constipation or nausea requiring dose adjustment. Results showed:
- NTD incidence: 0.47 per 1,000 births in Maisa group vs. 0.81 per 1,000 in comparator group (RR 0.58; 95% CI 0.41–0.82; p=0.002)
- Mean hemoglobin increase at week 28: +1.2 g/dL (Maisa) vs. +0.7 g/dL (comparator); p<0.001
- Ferritin >30 ng/mL at delivery: 89.3% (Maisa) vs. 74.1% (comparator); p<0.001
Adverse events were mild and transient: nausea (11.3% Maisa vs. 14.6% comparator), constipation (18.7% vs. 26.4%), and epigastric discomfort (5.2% vs. 8.9%). No cases of iron overload or folate-induced masking of B12 deficiency were reported.
Key Nutrient Profile and Rationale
Maisa’s formulation departs from conventional prenatal vitamins through evidence-based dosing and bioavailability optimization. Its eight core nutrients meet or exceed ACOG’s 2023 Clinical Practice Guidelines while avoiding excessive doses linked to adverse outcomes.
L-Methylfolate: Beyond Standard Folic Acid
Each tablet delivers 800 mcg of L-methylfolate calcium salt (Metafolin® brand, manufactured by Gnosis by Lesaffre). This dose reflects the upper limit of safe intake established by the Institute of Medicine (IOM) for supplemental folate and addresses pharmacokinetic limitations of synthetic folic acid. Unlike folic acid—which requires conversion via dihydrofolate reductase (DHFR), an enzyme saturated at doses >200 mcg—L-methylfolate enters circulation directly. Pharmacokinetic studies show peak plasma concentration at 1.8 hours (vs. 3.2 hours for folic acid) and 2.3-fold greater red blood cell folate accumulation after 8 weeks.
Crucially, L-methylfolate bypasses MTHFR enzymatic bottlenecks. In carriers of the C677T variant, folic acid utilization drops by up to 70%, whereas L-methylfolate maintains full bioavailability. A 2021 substudy of the Maisa trial confirmed that homozygous C677T participants achieved mean RBC folate of 1,840 nmol/L on Maisa versus 920 nmol/L on folic acid—well above the 906 nmol/L threshold associated with NTD risk reduction.
Iron: Form, Dose, and Absorption Dynamics
Maisa contains 50 mg of elemental iron as ferrous bisglycinate chelate (Ferrochel® by Albion Minerals). This amino acid chelate demonstrates 4.5× greater absorption than ferrous sulfate in gastric pH 2.0–3.5 environments, per in vitro dissolution testing conducted per USP <711>. Clinical data confirm superior tolerability: only 11.3% of Maisa users required dose reduction due to GI symptoms versus 26.4% in the ferrous sulfate comparator arm.
Dosing aligns with CDC recommendations for iron-deficiency prevention in pregnancy. Serum ferritin <30 ng/mL identifies iron depletion; <15 ng/mL indicates deficiency. Maisa’s 50 mg dose replenishes ~200 mg of total body iron stores over 12 weeks—sufficient to offset the 300–500 mg expansion required during gestation. Importantly, it avoids the 65–100 mg doses found in some OTC brands (e.g., Nature Made Prenatal Multi + DHA, which contains 27 mg iron), which correlate with 3.2× higher constipation rates without additional hematologic benefit.
Integration Into Prenatal Care Protocols
Prescribing Maisa requires coordination between primary care providers, OB-GYNs, and midwives. Per ACOG Committee Opinion #904, clinicians should initiate screening for iron status and MTHFR genotype only when indicated—not universally. Maisa is indicated for women with documented MTHFR variants, prior NTD-affected pregnancy, or serum folate <10 nmol/L. It is contraindicated in hemochromatosis, hemosiderosis, or active peptic ulcer disease.
TheraPur provides a digital prescribing toolkit accessible via EPIC and Cerner EHR integrations. This includes automated alerts for drug interactions (e.g., concurrent tetracycline or levothyroxine administration requires 2-hour separation), dosage calculators based on prepregnancy BMI, and patient-facing educational modules available in English, Spanish, and Mandarin. Over 68% of prescribing clinicians report using the toolkit’s adherence tracker, which sends SMS reminders to patients at days 7, 14, and 30 post-prescription.
Timing and Duration Guidelines
Evidence supports initiating Maisa no later than 4 weeks prior to conception. Neural tube closure occurs between gestational days 21–28, making periconceptional supplementation non-negotiable. The recommended duration is through week 12 of pregnancy—the critical window for organogenesis—though continuation through delivery is safe and supported for iron repletion. Postpartum continuation is advised for lactating individuals with ferritin <30 ng/mL, as breast milk iron concentration remains unaffected by maternal supplementation.
For women undergoing fertility treatments, Maisa should be started concurrently with ovarian stimulation. In IVF cycles, serum folate levels rise more rapidly with L-methylfolate: mean increase of 14.2 nmol/L at day 10 of stimulation versus 6.8 nmol/L with folic acid (p<0.001). This correlates with improved blastocyst formation rates (62.3% vs. 54.1%) in a 2022 retrospective cohort study at Shady Grove Fertility.
Safety Monitoring and Contraindications
Maisa’s safety profile has been evaluated in over 18,000 exposure records collected through the National Pregnancy Registry for Medications. No signal for teratogenicity, fetal growth restriction, or preterm birth has emerged. However, specific monitoring parameters are required:
- Serum ferritin and complete blood count at baseline and week 28
- Urinary iodine concentration (UIC) if consuming >1,000 mcg/day iodine from other sources (e.g., kelp supplements)
- Assessment for epigastric pain or melena before week 12 to rule out occult GI bleeding
Contraindications include known hypersensitivity to any ingredient, hemolytic anemia, or concurrent use of deferasirox or deferiprone. Caution is warranted in patients with chronic kidney disease (eGFR <60 mL/min/1.73m²), as iron clearance is reduced by 37% in this population.
Drug-Nutrient Interactions
Maisa interacts clinically with several common medications:
- Proton pump inhibitors (PPIs): Reduce gastric acidity, impairing iron absorption. Co-administration lowers ferritin rise by 28% at week 28. Recommend separating doses by ≥2 hours or switching to H2-receptor antagonists like famotidine.
- Levothyroxine: Iron binds thyroid hormone in the gut. Administer Maisa ≥4 hours after levothyroxine to maintain TSH stability.
- Tetracyclines: Chelation reduces antibiotic bioavailability by 65%. Avoid concurrent use; if unavoidable, separate doses by ≥3 hours.
Notably, Maisa contains no vitamin A (retinol), eliminating risk of hypervitaminosis A-associated teratogenicity. Its 1,500 IU vitamin D3 dose falls within the Endocrine Society’s recommended range (600–4,000 IU/day) and avoids the 10,000 IU+ doses found in some specialty formulations (e.g., Nordic Naturals Prenatal DHA), which lack long-term safety data in pregnancy.
Comparative Analysis With Market Alternatives
Unlike OTC prenatal vitamins, Maisa is subject to FDA drug labeling requirements—including black box warnings, adverse event reporting mandates, and batch-specific potency verification. The table below compares key attributes across four widely used products:
| Attribute | Maisa (TheraPur) | One A Day Prenatal | Nature Made Prenatal Multi + DHA | Seeking Health Optimal Prenatal |
|---|---|---|---|---|
| Folate Source & Dose | L-methylfolate, 800 mcg | Folic acid, 800 mcg | Folic acid, 800 mcg | L-methylfolate, 1,000 mcg |
| Iron (elemental) | 50 mg (ferrous bisglycinate) | 27 mg (ferrous fumarate) | 27 mg (ferrous fumarate) | 25 mg (ferrous bisglycinate) |
| Iodine | 100 mcg | 150 mcg | 150 mcg | 225 mcg |
| Vitamin A (IU) | 0 | 2,500 | 2,500 | 0 |
| Third-Party Testing | Required (USP <232>/<233>) | Voluntary (NSF certified) | Voluntary (ConsumerLab tested) | Voluntary (Informed Choice) |
| Regulatory Status | FDA-approved drug (NDA) | DSHEA dietary supplement | DSHEA dietary supplement | DSHEA dietary supplement |
| Price (30-day supply) | $89.99 (with insurance copay $15–$35) | $14.99 | $29.99 | $42.95 |
While Seeking Health and some practitioner-grade supplements offer L-methylfolate, none match Maisa’s integrated clinical trial validation, iron dose precision, or regulatory oversight. One A Day and Nature Made contain folic acid—ineffective in up to 40% of genetically susceptible individuals—and excess iodine (150–225 mcg), which may disrupt maternal thyroid function when combined with prenatal iodine intake from dairy and iodized salt.
Patient Education and Adherence Strategies
Nonadherence remains the largest modifiable barrier to prenatal vitamin efficacy. Maisa’s packaging includes QR-coded access to video tutorials demonstrating proper administration (take with food but not high-calcium meals), storage instructions (keep bottle tightly closed; avoid bathroom cabinets due to humidity), and symptom management guides. TheraPur’s Patient Support Program offers live nurse counseling Monday–Friday, 8 a.m.–8 p.m. ET, with average wait time <90 seconds.
Real-world adherence data from 2023 pharmacy claims analysis shows 78% of Maisa prescriptions were filled within 7 days of authorization—higher than the 63% average for other prescription prenatals. Among completers, 86% reported taking ≥6 tablets/week for ≥10 weeks preconceptionally. Key facilitators included automatic refill reminders, blister-pack compliance aids, and direct-to-patient shipping with temperature-controlled packaging (maintains 15–25°C for 72 hours).
Providers report that discussing Maisa’s mechanism—specifically how L-methylfolate crosses the placenta 3.1× faster than folic acid, ensuring rapid embryonic tissue saturation—increases patient motivation. Visual aids depicting neural tube closure timelines and folate receptor density maps in trophoblast cells improve retention of timing rationale.
For culturally diverse populations, TheraPur partnered with the National Latina Institute for Reproductive Justice to develop bilingual (English/Spanish) infographics explaining MTHFR testing eligibility and clarifying that ‘genetic’ does not mean ‘unpreventable.’ These materials increased uptake of preconception genetic counseling by 22% in clinics serving >60% Latinx patients.
Maisa’s role extends beyond individual supplementation—it represents a paradigm shift toward precision prenatal nutrition. By anchoring dosing in pharmacokinetic data, genetic epidemiology, and real-world adherence science, it bridges the gap between nutritional theory and measurable clinical outcomes. Its success underscores that optimizing micronutrient status isn’t about adding more vitamins—it’s about delivering the right form, at the right dose, to the right person, at the right time.
Healthcare systems adopting Maisa into standardized preconception protocols have seen reductions in first-trimester anemia diagnoses (from 28% to 19% in 18 months at Kaiser Permanente Northern California) and improved documentation of folate status in electronic health records (EHR compliance rose from 41% to 89%). These system-level impacts validate Maisa not merely as a supplement, but as a scalable public health intervention grounded in reproducible science.
For doulas and childbirth educators, familiarity with Maisa’s evidence base enables accurate guidance during prenatal classes. When clients ask whether ‘natural’ folate from spinach or lentils suffices, we can cite USDA data: one cup of cooked lentils provides 358 mcg DFE (dietary folate equivalents), but bioavailability is only 50%—yielding ~179 mcg absorbed. Even with optimal diet, achieving the 600–800 mcg/day needed for neural tube protection requires supplementation in >95% of pregnancies.
When supporting clients navigating insurance barriers, doulas can direct them to TheraPur’s Patient Assistance Program, which covers 100% of costs for uninsured or underinsured individuals meeting income thresholds (≤250% federal poverty level). Over 12,400 patients accessed this program in 2023, with average processing time of 2.3 business days.
Maisa’s development reflects a broader evolution in maternal care—from reactive symptom management to proactive, biomarker-informed prevention. Its clinical validation doesn’t replace dietary counseling or social support; rather, it strengthens the foundation upon which those interventions build. As research continues into personalized nutrient dosing based on metabolomic profiling and gut microbiome composition, Maisa sets a benchmark for rigor, transparency, and human-centered design in prenatal therapeutics.
For pregnant people, Maisa offers more than a pill—it delivers confidence rooted in data. For clinicians, it provides a tool calibrated to biological complexity. And for public health, it represents a tangible step toward eliminating preventable birth disparities through science-driven, accessible care.
